Introducing Generative Biology Revolution, a New Serial Podcast from Amgen R&D Exploring How AI-Powered Protein Design Is Transforming Drug Discovery

Join host Ray Deshaies, Amgen’s senior vice president of Global Research, in conversations with leading scientific experts about the potential to enhance the speed and efficiency of biologics discovery.

Beginning June 23, Amgen’s R&D podcast series returns with Generative Biology Revolution. Produced in partnership with The Scientist, Generative Biology Revolution explores new transformational approaches to drug discovery and development that leverage artificial intelligence (AI) and machine learning to design novel protein therapeutics.

Identifying and optimizing biologics is a slow, iterative process, where scientists must constantly tweak potential therapeutics to improve their activity and safety. In 2021, the world changed for drug research and discovery when researchers published advances that used AI and machine learning to predict the structure of human proteins. With breakthroughs like this, scientists are reimagining protein drug discovery and design where they strive to leave the guesswork behind and instead use computers to quickly tailor biological molecules for therapeutic purposes.

In this series, Ray Deshaies, Ph.D., senior vice president of Global Research at Amgen, discusses how generative biology works and how it is transforming drug discovery to make it more predictable, shorten timelines, and increase success rates of bringing potentially life-saving medicines to patients who need them most.

“Last year, our podcasts explored the role of genetics in drug discovery and how new multispecific medicines are being designed to tackle undruggable disease targets. With our new podcast series, Generative Biology Revolution, we are now looking at how the intersection of lab research and technology is being used to help scientists quickly tailor biological molecules and accelerate drug discovery,” said Deshaies. “I’m excited to share the conversations with a terrific roster of experts as we explore this exciting and evolving field.”

Joining Deshaies are leaders from Amgen and premier research institutions discussing topics ranging from explaining this new era in transformational science to how researchers are accelerating drug discovery with protein structure prediction and design.

The first episode launches June 23, and the series continues with a new episode every Thursday through July 14. You can find Generative Biology Revolution here or by subscribing to The Scientist’s series LabTalk on Apple Podcasts, Spotify, Stitcher, Google Podcasts, or wherever you like to listen.

June 23: The Cresting Wave of Transformational Science
Alan Russell, Ph.D., vice president of Biologics at Amgen

June 30: The Protein Structure Prediction Problem
Mike Nohaile, Ph.D., chief scientific officer at Generate Biomedicines

July 7: Protein Design from Scratch
David Baker, Ph.D., director of the Institute for Protein Design at the University of Washington

July 14: Accelerating Drug Discovery with Protein Design
Suzanne Edavettal, Ph.D., executive director of Protein Engineering at Amgen

In addition to the podcast series, Amgen and The Scientist will offer a live webinar with Marissa Mock, Ph.D., director of Generative Biology at Amgen, to dig deeper into the science behind the latest technologies in generative biology. Register to listen here.

Generative Biology Revolution is the third Amgen podcast produced in partnership with The Scientist. You can find the first two series, DNA Unlocked and Undruggable, here.

Share This Story